Portfolio Companies News
September 20, 2017ALTIMMUNE ANNOUNCES ITS PHASE 2 FLU...
60 Patients to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA to initiate their Phase 2 clinical stu... read more
September 20, 2017Bonesupport™ – Data presented a...
Lund, Sweden, 08.00 CEST, 20 September 2017 – BONESUPPORT an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT platform announces that a pre-clinical stud... read more
September 19, 2017Bonesupport appoints Jerry Chang as...
Lund, Sweden, 12.00 CEST, 19 September 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has appointed Dr... read more
September 19, 2017GenSight Biologics integrates the C...
Paris, France, September 19, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced its sto... read more
September 14, 2017Targovax Receives 2017 Nordic Stars...
Oslo, Norway, 14 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that they are one of three companies to have been selected for this year's Nordic Stars Awards, pre... read more
July 14, 2017Q2 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 108 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.